Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment

Clinical and Vaccine Immunology

Volumn 15, Issue 2, 2008, Pages 267-276

  Currier, Jeffrey R ^a   Galley, Lynee M ^a   Wenschuh, Holger ^b   Morafo, Vivian ^c   Ratto Kim, Silvia ^d   Gray, Clive M ^c   Maboko, Leonard ^e   Hoelscher, Michael ^f   Marovich, Mary A ^a   Cox, Josephine H ^a  

^a US Military HIV Research Program   (United States)

^b JPT Peptide Technologies GmbH   (Germany)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^e Mbeya Medical Research Programme   (Tanzania)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; PEPTIDE LIBRARY; SYNTHETIC PEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS PROTEIN;

ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG IMPURITY; DRUG QUALITY; FALSE POSITIVE RESULT; FLOW CYTOMETRY; HIGH THROUGHPUT SCREENING; HLA SYSTEM; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PERFORMANCE; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY; T LYMPHOCYTE; VALIDATION PROCESS; CHEMISTRY; CYTOMEGALOVIRUS; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DRUG CONTAMINATION; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; STANDARD;

AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; DRUG CONTAMINATION; HIV; HIV-1; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PEPTIDE LIBRARY; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; VIRAL PROTEINS;

EID: 40449131603     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00284-07     Document Type: Article

References (30)

1. Addo, M. M., X. G. Yu, A. Rathod, D. Cohen, R. L. Eldridge, D. Strick, M. N. Johnston, C. Corcoran, A. G. Wurcel, C. A. Fitzpatrick, M. E. Feeney, W. R. Rodriguez, N. Basgoz, R. Draenert, D. R. Stone, C. Brander, P. J. Goulder, E. S. Rosenberg, M. Altfeld, and B. D. Walker. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses but no correlation to viral load. J. Virol. 77:2081-2092.
2. Beattie, T., R. Kaul, T. Rostron, T. Dong, P. Easterbrook, W. Jaoko, J. Kimani, F. Plummer, A. McMichael, and S. Rowland-Jones. 2004. Screening for HIV-specific T-cell responses using overlapping 15-mer peptide pools or optimized epitopes. AIDS 18:1595-1598.
3. + T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75:11983-11991.
4. Cox, J. H., G. Ferrari, S. A. Kalams, W. Lopaczynski, N. Oden, and P. M. D'Souza. 2005. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res. Hum. Retrovir. 21:68-81.
5. Currier, J. R., E. G. Kuta, E. Turk, L. B. Earhart, L. Loomis-Price, S. Janetzki, G. Ferrari, D. L. Birx, and J. H. Cox. 2002. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260:157-172.
6. Currier, J. R., U. Visawapoka, S. Tovanabutra, C. J. Mason, D. L. Birx, F. E. McCutchan, and J. H. Cox. 2006. CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detectable breadth of the CTL response. BMC Immunol. 7:8.
7. de Beukelaar, J. W., J. W. Gratama, P. A. Smitt, G. M. Verjans, J. Kraan, T. M. Luider, and P. C. Burgers. 2007. The impact of impurities in synthetic peptides on the outcome of T-cell stimulation assays. Rapid Commun. Mass Spectrom. 21:1282-1288.
8. Draenert, R., M. Altfeld, C. Brander, N. Basgoz, C. Corcoran, A. G. Wurcel, D. R. Stone, S. A. Kalams, A. Trocha, M. M. Addo, P. J. Goulder, and B. D. Walker. 2003. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J. Immunol. Methods 275:19-29.
9. Draenert, R., C. Brander, X. G. Yu, M. Altfeld, C. L. Verrill, M. E. Feeney, B. D. Walker, and P. J. Goulder. 2004. Impact of intrapeptide epitope location on CD8 T cell recognition: implications for design of overlapping peptide panels. AIDS 18:871-876.
10. Findlay, J. W., W. C. Smith, J. W. Lee, G. D. Nordblom, I. Das, B. S. DeSilva, M. N. Khan, and R. R. Bowsher. 2000. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21:1249-1273.
11. Frahm, N., B. T. Korber, C. M. Adams, J. J. Szinger, R. Draenert, M. M. Addo, M. E. Feeney, K. Yusim, K. Sango, N. V. Brown, D. SenGupta, A. Piechocka-Trocha, T. Simonis, F. M. Marincola, A. G. Wurcel, D. R. Stone, C. J. Russell, P. Adolf, D. Cohen, T. Roach, A. StJohn, A. Khatri, K. Davis, J. Mullins, P. J. Goulder, B. D. Walker, and C. Brander. 2004. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J. Virol. 78:2187-2200.
12. Fu, T. M., S. A. Dubey, D. V. Mehrotra, D. C. Freed, W. L. Trigona, L. Adams-Muhler, J. H. Clair, T. G. Evans, R. Steigbigel, J. M. Jacobson, P. A. Goepfert, M. J. Mulligan, S. A. Kalams, C. Rinaldo, L. Zhu, K. S. Cox, L. Guan, R. Long, N. Persaud, M. J. Caulfield, J. C. Sadoff, E. A. Emini, S. Thaler, and J. W. Shiver. 2007. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res. Hum. Retrovir. 23:67-76.
13. Geldmacher, C, J. R. Currier, M. Gerhardt, A. Haule, L. Maboko, D. Birx, C. Gray, A. Meyerhans, J. Cox, and M. Hoelscher. 2007. In a mixed subtype epidemic, the HIV-1 Gag-specific T-cell response is biased towards the infecting subtype. AIDS 21:135-143.
14. Gibson, L., G. Piccinini, D. Lilleri, M. G. Revello, Z. Wang, S. Markel, D. J. Diamond, and K. Luzuriaga. 2004. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J. Immunol. 172:2256-2264.
15. Glaser, V. 2006. Market growing for custom-made peptides. GEN 26:38-40.
16. Hudgens, M. G., S. G. Self, Y. L. Chiu, N. D. Russell, H. Horton, and M. J. McElrath. 2004. Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials. J. Immunol. Methods 288:19-34.
17. Janetzki, S., J. H. Cox, N. Oden, and G. Ferrari. 2005. Standardization and validation issues of the ELISPOT assay. Methods Mol. Biol. 302:51-86.
18. Karlsson, R. K., W. Jennes, K. Page-Shafer, D. F. Nixon, and B. L. Shacklett. 2004. Poorly soluble peptides can mimic authentic ELISPOT responses. J. Immunol. Methods 285:89-92.
19. Kern, F., I. P. Surel, C. Brock, B. Freistedt, H. Radtke, A. Scheffold, R. Blasczyk, P. Reinke, J. Schneider-Mergener, A. Radbruch, P. Walden, and H. D. Volk. 1998. T-cell epitope mapping by flow cytometry. Nat. Med. 4:975-978.
20. Los Alamos National Laboratory. 2006. PeptGen: creates sets of overlapping peptides for proteins to aid in peptide design for mapping epitopes. HIV Molecular Immunology Database. http://www.hiv.lanl.gov/content/hiv-db /PEPTGEN/PeptGenSubmitForm.html.
21. Maecker, H., J. Moon, S. Bhatia, S. Ghanekar, V. Maino, J. Payne, K. Kuus-Reichel, J. Chang, A. Summers, T. Clay, M. Morse, H. K. Lyerly, C. DeLaRosa, D. Ankerst, and M. Disis. 2005. Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol. 6:17.
22. Maecker, H. T., H. S. Dunn, M. A. Suni, E. Khatamzas, C. J. Pitcher, T. Bunde, N. Persaud, W. Trigona, T. M. Fu, E. Sinclair, B. M. Bredt, J. M. McCune, V. C. Maino, F. Kern, and L. J. Picker. 2001. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 255:27-40.
23. Mannering, S. I., A. W. Purcell, M. C. Honeyman, J. McCluskey, and L. C. Harrison. 2003. Human T-cells recognise N-terminally Fmoc-modified pep-tide. Vaccine 21:3638-3646.
24. Moodie, Z., Y. Huang, L. Gu, J. Hural, and S. G. Self. 2006. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J. Immunol. Methods 315:121-132.
25. Najafian, N., A. D. Salama, E. V. Fedoseyeva, G. Benichou, and M. H. Sayegh. 2002. Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J. Am. Soc. Nephrol. 13:252-259.
26. Ohnishi, M., T. Sakurai, Y. Heike, R. Yamazaki, Y. Kanda, Y. Takaue, H. Mizoguchi, and Y. Kawakami. 2005. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Br. J. Haematol. 131:472-479.
27. Russell, N. D., M. G. Hudgens, R. Ha, C. Havenar-Daughton, and M. J. McElrath. 2003. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J. Infect. Dis. 187:226-242.
28. Trigona, W. L., J. H. Clair, N. Persaud, K. Punt, M. Bachinsky, U. Sadasivan-Nair, S. Dubey, L. Tussey, T. M. Fu, and J. Shiver. 2003. Intracellular staining for HIV-specific IFN-gamma production: statistical analyses establish reproducibility and criteria for distinguishing positive responses. J. Interf. Cytok. Res. 23:369-377.
29. Whiteside, T. L., Y. Zhao, T. Tsukishiro, E. M. Elder, W. Gooding, and J. Baar. 2003. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res. 9:641-649.
30. Wills, M. R., A. J. Carmichael, K. Mynard, X. Jin, M. P. Weekes, B. Plachter, and J. G. Sissons. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70:7569-7579.